Sun Pharmaceutical Industries and Germantown, Maryland-based Intrexon will develop controllable gene-based therapies for eye diseases in a joint venture that combines Sun Pharma's specialty product development and manufacturing expertise – and the Mumbai, India company's global reach – with Intrexon's synthetic biology technology.
The partners will split the costs and revenue associated with their product candidates, which will focus initially on dry age-related...






